Contact Information: For further information contact: David Carey Lazar Partners Ltd. (646) 239-6231
Electro-Optical Sciences Announces Participation at the Sixth Annual Needham & Co. Biotechnology and Medical Technology Conference
| Source: Electro-Optical Sciences
IRVINGTON, NY--(Marketwire - June 7, 2007) - Electro-Optical Sciences, Inc. ("EOS")
(NASDAQ : MELA ), a medical device company focused on the design and
development of MelaFind®, a non-invasive, point-of-care instrument to
assist in the early diagnosis of melanoma, today announced that Joseph V.
Gulfo, MD, MBA, president and chief executive officer, will present at the
Sixth Annual Needham & Co. Biotechnology and Medical Technology Conference
taking place at the New York Palace Hotel in New York June 13 - 14, 2007.
Dr. Gulfo's presentation is scheduled for Thursday, June 14 at 10:30am ET.
To access the live webcast of this presentation visit www.eosciences.com. A
replay of this presentation will be available on the company's website for
two weeks following the presentation.
About Electro-Optical Sciences
EOS is a medical device company focused on designing and developing a
non-invasive, point-of-care instrument to assist in the early diagnosis of
melanoma. MelaFind®, EOS's flagship product, features a hand-held imaging
device that emits light of multiple wavelengths to capture images of
suspicious pigmented skin lesions and extract data. Using sophisticated
algorithms, the data are then analyzed against a proprietary database of
melanomas and benign lesions in order to provide information to the
physician and produce a recommendation of whether the lesion should be
biopsied.
Melanoma is the deadliest of skin cancers, responsible for approximately
80% of all skin cancer deaths. Unless melanoma is detected early and
excised with proper margins, the patient survival rate is poor, as there is
currently no cure for advanced stage melanoma.
For more information on EOS, visit www.eosciences.com.
Safe Harbor
This press release includes "forward-looking statements" within the meaning
of the Securities Litigation Reform Act of 1995. These statements include
but are not limited to our plans, objectives, expectations and intentions
and other statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes" and variations of such words
or similar expressions that predict or indicate future events or trends, or
that do not relate to historical matters. These statements are based on our
current beliefs or expectations and are inherently subject to significant
uncertainties and changes in circumstances, many of which are beyond our
control. There can be no assurance that our beliefs or expectations will be
achieved. Actual results may differ materially from our beliefs or
expectations due to economic, business, competitive, market and regulatory
factors.